Analyst Price Targets — MNKD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 24, 2025 12:24 pm | — | Truist Financial | $9.00 | $5.03 | TheFly | MannKind initiated with a Buy at Truist |
| September 2, 2025 1:42 pm | — | H.C. Wainwright | $11.00 | $5.74 | TheFly | MannKind price target raised to $11 from $9 at H.C. Wainwright |
| August 26, 2025 11:28 am | Douglas Miehm | RBC Capital | $8.00 | $4.00 | TheFly | MannKind price target raised to $8 from $7 at RBC Capital |
| August 25, 2025 4:22 pm | — | H.C. Wainwright | $9.00 | $3.90 | TheFly | H.C. Wainwright positive on MannKind deal for scPharmaceuticals |
| August 28, 2024 7:55 am | Steven Lichtman | Oppenheimer | $12.00 | $5.38 | TheFly | MannKind price target raised to $12 from $10 at Oppenheimer |
| October 10, 2023 12:57 pm | Andreas Argyrides | Wedbush | $10.00 | $4.23 | Benzinga | MannKind Analyst Turns Bullish, Says 'Don't Call It Comeback' |
Latest News for MNKD
Investors weren't pleased with the biotech's bottom-line decline. It also missed the consensus analyst estimate for that metric.
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MNKD.
U.S. House Trading
No House trades found for MNKD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.